August 06, 2020

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

NRG Oncology opened a Phase II/III trial (NRG-BN007) to determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival for the Phase II patient cohort or overall survival for the Phase III patient cohort versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation.

Read the study